Ledipasvir

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1949888
                    [Title] => Ledipasvir/Sofosbuvir looks good in HBV-coinfected patients
                    [Summary] => For patients with chronic hepatitis C and hepatitis B virus co-infection, 12 weeks of ledipasvir/sofosbuvir therapy achieved a 100 percent sustained viral response rate without causing liver failure or death in a phase 3b, multicenter, open-label study.
                    [DatePublished] => 2019-09-08 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 1
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

abtest

Ledipasvir/Sofosbuvir looks good in HBV-coinfected patients

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | September 8, 2019 - 12:00am

For patients with chronic hepatitis C and hepatitis B virus co-infection, 12 weeks of ledipasvir/sofosbuvir therapy achieved a 100 percent sustained viral response rate without causing liver failure or death in a...

Opinion